All Teams: 6
BeiGene (BeOne)
Basel · est. 2010
BeiGene is the first Chinese biotech to successfully commercialize a blockbuster cancer drug globally; it is currently rebranding as a Swiss company to shed geopolitical baggage.
Hengrui Medicine
Lianyungang · est. 1970
Hengrui is the Pfizer of China; it survived brutal pricing crackdowns by ruthlessly reinvesting its profits to transform from a legacy generic manufacturer into an innovative powerhouse.
WuXi AppTec
Shanghai · est. 2000
WuXi AppTec is the invisible backbone of the global pharmaceutical industry; acting as the outsourced R&D lab for the worlds biggest drugmakers, it generates record profits despite US China decoupling.
Sino Biopharm
Hong Kong / Beijing · est. 2000
Sino Biopharm is the master of commercial partnerships; it utilizes its unparalleled sales network to distribute innovative drugs for global partners while building its own massive oncology and liver disease portfolio.
Mindray
Shenzhen · est. 1991
Mindray is the Medtronic of China; having completely replaced Western medical hardware in Chinese hospitals, it is now utilizing AI diagnostics to transform hardware into a digital ecosystem.
United Imaging
Shanghai · est. 2011
United Imaging is the 'Huawei of Medical Hardware'; it broke the 30-year monopoly of 'GPS' (GE, Philips, Siemens) in high end medical imaging by building Chinas first domestic PET CT and ultra high field MRI machines.
Scoreboard
Hengrui Medicine
Integrated Pharmaceutical R&D and Commercialization.
WuXi AppTec
B2B Outsourced Research and Manufacturing.
Sino Biopharm
Integrated Pharma
Mindray
Medical Hardware Manufacturing
United Imaging
High CapEx Hardware Sales
Play Styles
Rivalries
Watchlist
BeiGene (BeOne)
$3.8BFY2024BeiGene has finally crossed the biotech Valley of Death. It is no longer a speculative startup; it is a cash generating pharma major.
Hengrui Medicine
$3.9BHengrui's 2025 earnings prove the transition from cheap generics to premium innovative drugs is complete, with profit growth surging nearly 50 percent.
WuXi AppTec
$5.4BFY2024Despite US Biosecure Act threats, WuXi's massive 2025 backlog and 84 percent profit surge prove that Big Pharma currently cannot live without them.
Sino Biopharm
$4.2BSino Biopharm is aggressively divesting legacy, low growth assets to focus entirely on high margin innovation. In 2025, they announced several blockbuster clinical breakthroughs in oncology that are expected to drive double digit growth through 2030.